Therefore, the dual targeting of EGFR and HER-2 may be beneficial for EGFR over-expressing triple-negative breast cancer [40], for which CUDC-1010 would be an appealing HDACi candidate. This evidence concerns the gene EGFR and triple-negative breast carcinoma.